BioNTech to Acquire Autolus Therapeutics for $1.14B

Ticker: AUTL · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1730463

Autolus Therapeutics PLC 8-K Filing Summary
FieldDetail
CompanyAutolus Therapeutics PLC (AUTL)
Form Type8-K
Filed DateJun 5, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.000042
Sentimentbullish

Sentiment: bullish

Topics: acquisition, biotech, merger, oncology

Related Tickers: BNTX, AUTL

TL;DR

BioNTech is buying Autolus for $1.14B cash ($8/share) to boost its cancer therapy game.

AI Summary

Autolus Therapeutics plc announced on June 5, 2024, that it has entered into a definitive agreement to be acquired by BioNTech SE for approximately $1.14 billion. The transaction will be effected through a voluntary takeover offer by BioNTech UK Acquisition Limited, a wholly-owned subsidiary of BioNTech SE, to acquire all outstanding ordinary shares of Autolus. The offer price is $8.00 per Autolus share in cash, representing a significant premium over recent trading prices.

Why It Matters

This acquisition by BioNTech SE significantly expands its cell therapy pipeline and strengthens its position in the oncology market, potentially accelerating the development of new cancer treatments.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals and the acceptance of the offer by a majority of Autolus shareholders, which introduces some uncertainty.

Key Numbers

  • $1.14B — Acquisition Value (Total cash consideration for Autolus Therapeutics plc.)
  • $8.00 — Offer Price per Share (Cash amount offered for each Autolus ordinary share.)

Key Players & Entities

  • Autolus Therapeutics plc (company) — Company being acquired
  • BioNTech SE (company) — Acquiring company
  • BioNTech UK Acquisition Limited (company) — Subsidiary making the takeover offer
  • $1.14 billion (dollar_amount) — Total acquisition value
  • $8.00 (dollar_amount) — Offer price per share
  • June 5, 2024 (date) — Date of the announcement

FAQ

What is the total value of the acquisition agreement between BioNTech SE and Autolus Therapeutics plc?

The total value of the acquisition agreement is approximately $1.14 billion.

What is the offer price per Autolus Therapeutics plc share?

The offer price is $8.00 per Autolus share in cash.

Who is making the takeover offer for Autolus Therapeutics plc?

BioNTech UK Acquisition Limited, a wholly-owned subsidiary of BioNTech SE, is making the voluntary takeover offer.

What is the date of the earliest event reported in this Form 8-K?

The date of the earliest event reported is June 5, 2024.

What are the primary securities registered by Autolus Therapeutics plc on the Nasdaq?

Autolus Therapeutics plc has American Depositary Shares (ADS), each representing one ordinary share, and ordinary shares registered on The Nasdaq Global Select Market.

Filing Stats: 845 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-06-05 16:35:50

Key Financial Figures

  • $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec

Filing Documents

01 Other Events

Item 8.01 Other Events. On June 5, 2024, Autolus Therapeutics plc (the "Company") published its UK Annual Report and Accounts for the year ended December 31, 2023 (the "UK Annual Report") and distributed a notice of its annual general meeting to be held on June 28, 2024 (the "AGM"), a form of proxy and its UK Annual Report to its ordinary shareholders. The UK Annual Report, notice of the AGM and Form of Proxy are furnished herewith as Exhibits 99.1, 99.2, and 99.3, respectively, hereto. On or about June 5, 2024, Citibank, N.A., in its capacity as the depositary bank (the "Depositary") for the Company's American Depositary Shares ("ADSs"), commenced mailing notice materials and voting cards to ADS holders to enable ADS holders of record as of May 21, 2024 to instruct the Depositary to vote the ordinary shares represented by their ADSs. If the Depositary receives timely voting instructions from an ADS holder, it will endeavor to vote the ordinary shares (in person or by proxy) represented by the holder's ADSs in accordance with the ADS holder's voting instructions. The ability of the Depositary to carry out voting instructions may be limited by practical and legal limitations and ADS holders may not receive voting materials in time to enable them to return voting instructions to the Depositary in a timely manner. The notice materials to be mailed by the Depositary to ADS holders will contain a link to the Company's website where ADS holders can view and download the AGM notice distributed by the Company to its ordinary shareholders (which contains explanatory notes for the resolutions being voted on at the AGM) and the UK Annual Report. The information contained in Exhibits 99.1, 99.2 and 99.3 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Annual Report and financial statements for the year ended 31 December 2023 99.2 Notice of Annual General Meeting 99.3 Form of Proxy 104 Cover Page Interactive Data File (embedded within XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: June 5, 2024 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.